IRB #

STUDY00019009

Title

A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Principal Investigator

Jeremy Cetnar

Study Purpose

The purpose of this study is to test the safety, tolerability and effectiveness (how well the drug works), of the combination of two investigational drugs called nivolumab and ipilimumab in subjects with non-small cell lung cancer (NSCLC).

Medical Condition(s)

non-small cell lung cancer
NSCLC
Immunotherapy

Eligibility Criteria

Are 18 years of age or older
• Have confirmed diagnosis of stage IIIB or IV NSCLC
• May have brain metastases
• May have had prior chemotherapy or other cancer therapy

Age Range

18 - 150

Healthy Volunteers Needed

No

Duration of Participation

Up to 10 years

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Bristol-Myers Squibb Research and Development

Recruitment End

09/05/2023

Compensation Provided

No


Go Back